[Effect of gMDSCs on natural killer cell functionality in chronic hepatitis C patients treated with direct-acting

J J Shi1, W J Zhou2, C Lu1

  • 1Key Medical Laboratory of Stem Cell Transformation and Application,the First People's Hospital of Zhengzhou, Zhengzhou 450000, China.

Insights

Granulocytic myeloid-derived suppressor cells (G-MDSCs) impair natural killer (NK) cell function in chronic hepatitis C (CHC) patients by suppressing IFN-γ production. Direct-acting antiviral (DAA) treatment normalizes NK cell function and reduces G-MDSCs.

Area of Science:

  • Immunology
  • Hepatology
  • Virology

Background:

  • Chronic hepatitis C (CHC) is associated with altered immune cell function.
  • Natural killer (NK) cells play a crucial role in viral clearance.
  • Granulocytic myeloid-derived suppressor cells (G-MDSCs) are implicated in immune suppression.

Purpose of the Study:

  • To investigate NK cell function changes in treatment-naive CHC patients.
  • To clarify the effect of G-MDSCs on NK cell functionality before and after direct-acting antiviral (DAA) therapy.
  • To explore the regulatory mechanisms of G-MDSCs on NK cells.

Main Methods:

  • Prospective study of 13 treatment-naive CHC patients and 13 healthy controls.
  • Flow cytometry to assess peripheral blood NK cell subsets and G-MDSC frequencies.
  • In vitro co-culture experiments of NK cells and G-MDSCs to determine regulatory mechanisms.

Main Results:

  • CHC patients exhibited decreased NK cell IFN-γ production and increased CD107a degranulation compared to controls.
  • Elevated frequencies of G-MDSCs and plasma arginase-1 were observed in CHC patients.
  • DAA treatment led to increased NK cell IFN-γ production, decreased CD107a degranulation, and reduced G-MDSC frequencies.

Conclusions:

  • G-MDSCs suppress NK cell IFN-γ production in CHC patients in an arginase I-dependent manner.
  • DAA-mediated HCV clearance is associated with the normalization of NK cell function and G-MDSC frequency.
  • Targeting G-MDSCs may represent a therapeutic strategy in CHC management.